| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.85B | 6.15B | 5.25B | 5.52B | 5.78B | 5.35B |
| Gross Profit | 5.03B | 4.40B | 3.54B | 3.84B | 4.34B | 3.98B |
| EBITDA | 2.33B | 1.96B | 1.28B | 1.17B | 1.59B | 1.30B |
| Net Income | 1.33B | 1.06B | 343.00M | 418.00M | 1.06B | 732.00M |
Balance Sheet | ||||||
| Total Assets | 17.19B | 17.35B | 15.54B | 15.87B | 14.21B | 13.32B |
| Cash, Cash Equivalents and Short-Term Investments | 2.01B | 1.76B | 923.00M | 1.14B | 1.48B | 1.52B |
| Total Debt | 2.88B | 3.03B | 3.04B | 2.90B | 2.12B | 2.75B |
| Total Liabilities | 7.50B | 7.32B | 6.56B | 6.80B | 5.82B | 6.05B |
| Stockholders Equity | 9.68B | 10.03B | 8.97B | 9.06B | 8.39B | 7.27B |
Cash Flow | ||||||
| Free Cash Flow | 1.25B | 920.00M | 445.00M | 748.00M | 1.06B | 732.00M |
| Operating Cash Flow | 1.58B | 1.24B | 761.00M | 1.12B | 1.55B | 1.08B |
| Investing Cash Flow | 286.00M | 282.00M | -440.00M | -1.58B | -487.00M | -2.23B |
| Financing Cash Flow | -691.00M | -818.00M | -308.00M | 70.00M | -1.12B | 1.18B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $53.49B | 37.14 | 13.80% | 0.56% | 26.28% | 457.14% | |
| ― | $50.39B | 38.98 | 24.75% | ― | 89.58% | ― | |
| ― | $21.73B | 16.22 | 15.92% | 2.33% | 3.04% | 53.03% | |
| ― | $61.26B | 14.56 | 15.34% | 0.45% | 5.38% | 3.58% | |
| ― | $60.75B | ― | -257.82% | ― | 5.01% | -330.09% | |
| ― | $25.40B | ― | -1.81% | ― | 7.51% | 30.53% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
UCB S.A. Reports Strong First Half of 2025 Amid Revenue Growth and Positive Outlook
UCB S.A. is a global biopharmaceutical company headquartered in Brussels, Belgium, focusing on innovative treatments for severe diseases of the immune and central nervous systems.